Barry Horowitz, MD
Endocrinology, Diabetes & Metabolism · West Palm Beach, FLNPI 1437163003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $555,957 of the $627,743 with a category attached, or 88.6%. Lilly USA, LLC accounts for 67.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $153,213 and has fallen 60.9% since, to $59,942 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,521 payments — averaging $412.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$423K
- Novo Nordisk$107K
- AstraZeneca$36K
- Johnson & Johnson$16K
- AbbVie$12K
- Esperion Therapeutics, Inc.$7K
- plus $26K from 54 others
Across 569 payments — averaging $11,379 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.7M
- Incyte Corporation$1.6M
- AbbVie$754K
- Abbott$520K
- Medtronic$304K
- GSK$206K
- plus $391K from 7 others
What the payments were for
- Consulting fees$32,0155%
- Speaking & faculty fees$555,95789%
- Travel & lodging$15,9203%
- Food & beverage$22,6754%
- Education$380%
- Gifts$1,1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$201,903
- TRULICITY$147,422
- RYBELSUS$44,981
- Ozempic$44,143
- FARXIGA$35,232
- HUMULIN$29,900
- LYUMJEV$26,900
- INVOKANA$15,653
- Tresiba$12,815
- ARMOUR THYROID$7,665
- NEXLIZET$6,900
- NEXLETOL$6,900
- STEGLATRO$4,731
- Synthroid$3,900
- t:slim X2 Insulin Pump with Control-IQ$3,026
- 25-OH Vitamin D ST AIA-Pack$2,156
- QSYMIA$2,100
- FreeStyle Libre Pro$1,750
- CYCLOSET$1,513
- TU, ST, AIA-PACK$539
How this compares
$627,743 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 488 | $666,464 |
| MounjaroTirzepatide | 437 | $580,242 |
| TrulicityDulaglutide | 260 | $358,637 |
| JardianceEmpagliflozin | 299 | $319,979 |
| FarxigaDapagliflozin Propanediol | 147 | $159,419 |
| Tresiba Flextouch U-200Insulin Degludec | 188 | $129,079 |
| JanuviaSitagliptin Phosphate | 86 | $100,891 |
| RybelsusSemaglutide | 39 | $59,986 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $59,002 |
| SynthroidLevothyroxine Sodium | 540 | $51,654 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $46,198 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $36,568 |
| TymlosAbaloparatide | 14 | $36,337 |
| FiaspInsulin Aspart (Niacinamide) | 18 | $34,969 |
| TradjentaLinagliptin | 22 | $30,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $422,993 | $967,701758 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Xultophy 100-3.6 | $107,457 | $795,124616 claims |
| Boehringer IngelheimJardiance, Tradjenta | $604 | $350,545321 claims |
| MerckJanuvia, Janumet Xr, Janumet | $4,909 | $168,583135 claims |
| AstraZenecaFarxiga | $36,101 | $159,419147 claims |
| AbbVieSynthroid | $12,119 | $51,654540 claims |
| Radius Health, Inc.Tymlos | $264 | $36,33714 claims |
| Antares Pharma, Inc.Xyosted | $317 | $30,39719 claims |
| AmgenProlia | $1,452 | $27,20716 claims |
| Johnson & JohnsonInvokana | $15,953 | $26,94329 claims |
| BayerKerendia | $1,025 | $19,38216 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $201 | $11,1751,073 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in West Palm Beach
- William KayeWest Palm Beach$515K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.